Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

INTRODUCTION: Long-term safety data are critical for evaluating therapies for psoriasis. Ixekizumab has demonstrated efficacy and is well tolerated for the treatment of moderate-to-severe plaque psoriasis. We examined the safety and tolerability of up to 5 years of ixekizumab therapy in patients wit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Dermatol Ther (Heidelb)
Main Authors: Armstrong, April, Paul, Carle, Puig, Luis, Boehncke, Wolf Henning, Freeman, Michael, Torii, Hideshi, Papp, Kim, Griffiths, Christopher E. M., Blauvelt, Andrew, Reich, Kristian, Gooderham, Melinda, Terui, Tadashi, Renda, Lisa, Agada, Noah, Xu, Wen, Gallo, Gaia, Lebwohl, Mark G.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Healthcare 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6994584/
https://ncbi.nlm.nih.gov/pubmed/31749092
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13555-019-00340-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados